Cargando…
RF16 | PSUN155 Empagliflozin and the risk of nephrolithiasis
AIMS: Nephrolithiasis is a common disease, estimated to affect 10% of the US population. In addition to pain, often severe, it can lead to urinary tract infections and acute kidney injury, while contributing to health care costs from emergency room visits and follow-up interventions necessary to rel...
Autores principales: | Balasubramanian, Priyadarshini, Wanner, Christoph, Ferreira, João Pedro, Ofstad, Anne Pernille, Elsaesser, Amelie, Zinman, Bernard, Inzucchi, Silvio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625761/ http://dx.doi.org/10.1210/jendso/bvac150.878 |
Ejemplares similares
-
Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?
por: Balasubramanian, Priyadarshini, et al.
Publicado: (2022) -
RF16 | PSUN177 Predictors of Postpartum Depressive Symptoms in Women with Recent GDM
por: Dias, Jennifer, et al.
Publicado: (2022) -
PSUN250 Empagliflozin Induced Bladder Cancer in an Adult Patient With Latent Autoimmune Diabetes
por: Alzenaidi, Ahlam, et al.
Publicado: (2022) -
RF16 | PSUN170 Prevalence of Fournier's Gangrene in T2DM Treated with Oral Antiglycemic Medications
por: Engel, Ashley, et al.
Publicado: (2022) -
RF16 | PSUN335 Clinical Effects of Sodium Glucose Transporter Type 2 Inhibitors in Patients with Severe Insulin Resistance
por: Bansal, Rashika, et al.
Publicado: (2022)